Bayer Aktiengesellschaft Logo

Bayer Aktiengesellschaft

BAYRY

(2.5)
Stock Price

4,91 USD

-1.98% ROA

-2.61% ROE

-5.7x PER

Market Cap.

28.855.055.098,36 USD

130.52% DER

0.29% Yield

-1.88% NPM

Bayer Aktiengesellschaft Stock Analysis

Bayer Aktiengesellschaft Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bayer Aktiengesellschaft Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.99x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

3 ROE

The stock's ROE falls within an average range (8.27%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (5.34%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

6 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

7 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

9 DER

The company has a high debt to equity ratio (116%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-8) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Bayer Aktiengesellschaft Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bayer Aktiengesellschaft Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Bayer Aktiengesellschaft Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bayer Aktiengesellschaft Revenue
Year Revenue Growth
1998 28.062.000.000
1999 27.320.000.000 -2.72%
2000 29.561.441.360 7.58%
2001 28.987.886.720 -1.98%
2002 28.984.582.550 -0.01%
2003 28.517.587.450 -1.64%
2004 29.735.880.800 4.1%
2005 27.362.398.480 -8.67%
2006 28.955.881.040 5.5%
2007 32.385.000.000 10.59%
2008 32.918.000.000 1.62%
2009 31.168.000.000 -5.61%
2010 35.088.000.000 11.17%
2011 36.528.000.000 3.94%
2012 39.760.000.000 8.13%
2013 40.157.000.000 0.99%
2014 42.239.000.000 4.93%
2015 46.324.000.000 8.82%
2016 46.769.000.000 0.95%
2017 35.015.000.000 -33.57%
2018 39.586.000.000 11.55%
2019 43.545.000.000 9.09%
2020 41.400.000.000 -5.18%
2021 44.081.000.000 6.08%
2022 50.739.000.000 13.12%
2023 41.368.000.000 -22.65%
2023 47.637.000.000 13.16%
2024 44.576.000.000 -6.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bayer Aktiengesellschaft Research and Development Expenses
Year Research and Development Expenses Growth
1998 1.811.000.000
1999 2.141.000.000 15.41%
2000 2.379.693.900 10.03%
2001 2.492.832.380 4.54%
2002 2.533.947.230 1.62%
2003 2.409.881.050 -5.15%
2004 2.105.338.720 -14.47%
2005 1.884.499.920 -11.72%
2006 2.297.316.080 17.97%
2007 2.578.000.000 10.89%
2008 2.653.000.000 2.83%
2009 2.746.000.000 3.39%
2010 3.053.000.000 10.06%
2011 2.932.000.000 -4.13%
2012 3.013.000.000 2.69%
2013 3.190.000.000 5.55%
2014 3.574.000.000 10.74%
2015 4.281.000.000 16.51%
2016 4.666.000.000 8.25%
2017 4.504.000.000 -3.6%
2018 5.246.000.000 14.14%
2019 5.342.000.000 1.8%
2020 7.126.000.000 25.04%
2021 5.412.000.000 -31.67%
2022 6.572.000.000 17.65%
2023 6.008.000.000 -9.39%
2023 5.371.000.000 -11.86%
2024 5.996.000.000 10.42%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bayer Aktiengesellschaft General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 760.000.000
1999 773.000.000 1.68%
2000 7.778.990.440 90.06%
2001 9.162.114.320 15.1%
2002 8.021.148.490 -14.22%
2003 8.159.452.280 1.7%
2004 7.862.931.120 -3.77%
2005 7.151.305.700 -9.95%
2006 8.133.044.460 12.07%
2007 1.772.000.000 -358.98%
2008 1.649.000.000 -7.46%
2009 1.623.000.000 -1.6%
2010 1.647.000.000 1.46%
2011 1.713.000.000 3.85%
2012 1.866.000.000 8.2%
2013 1.883.000.000 0.9%
2014 1.741.000.000 -8.16%
2015 2.098.000.000 17.02%
2016 2.256.000.000 7%
2017 2.026.000.000 -11.35%
2018 2.728.000.000 25.73%
2019 3.890.000.000 29.87%
2020 2.879.000.000 -35.12%
2021 2.962.000.000 2.8%
2022 2.838.000.000 -4.37%
2023 2.204.000.000 -28.77%
2023 2.453.000.000 10.15%
2024 2.752.000.000 10.86%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bayer Aktiengesellschaft EBITDA
Year EBITDA Growth
1998 9.139.000.000
1999 6.185.000.000 -47.76%
2000 5.286.434.100 -17%
2001 3.763.974.590 -40.45%
2002 4.891.595.010 23.05%
2003 3.526.287.230 -38.72%
2004 4.125.844.240 14.53%
2005 4.643.705.000 11.15%
2006 4.674.947.300 0.67%
2007 5.044.000.000 7.32%
2008 6.266.000.000 19.5%
2009 5.815.000.000 -7.76%
2010 6.286.000.000 7.49%
2011 6.918.000.000 9.14%
2012 8.420.000.000 17.84%
2013 8.017.000.000 -5.03%
2014 8.641.000.000 7.22%
2015 10.140.000.000 14.78%
2016 10.896.000.000 6.94%
2017 8.310.000.000 -31.12%
2018 6.822.000.000 -21.81%
2019 10.406.000.000 34.44%
2020 10.320.000.000 -0.83%
2021 10.031.000.000 -2.88%
2022 12.767.000.000 21.43%
2023 5.752.000.000 -121.96%
2023 12.342.000.000 53.39%
2024 8.288.000.000 -48.91%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bayer Aktiengesellschaft Gross Profit
Year Gross Profit Growth
1998 15.552.000.000
1999 13.735.000.000 -13.23%
2000 13.952.352.960 1.56%
2001 12.416.957.680 -12.37%
2002 11.459.464.250 -8.36%
2003 11.712.736.530 2.16%
2004 12.366.467.520 5.29%
2005 12.346.345.130 -0.16%
2006 13.680.850.640 9.75%
2007 16.033.000.000 14.67%
2008 16.462.000.000 2.61%
2009 16.033.000.000 -2.68%
2010 17.985.000.000 10.85%
2011 18.553.000.000 3.06%
2012 20.701.000.000 10.38%
2013 20.810.000.000 0.52%
2014 21.973.000.000 5.29%
2015 25.166.000.000 12.69%
2016 26.474.000.000 4.94%
2017 23.633.000.000 -12.02%
2018 22.576.000.000 -4.68%
2019 26.078.000.000 13.43%
2020 22.262.000.000 -17.14%
2021 27.265.000.000 18.35%
2022 30.868.000.000 11.67%
2023 22.120.000.000 -39.55%
2023 27.888.000.000 20.68%
2024 24.600.000.000 -13.37%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bayer Aktiengesellschaft Net Profit
Year Net Profit Growth
1998 1.614.000.000
1999 2.002.000.000 19.38%
2000 1.820.705.400 -9.96%
2001 966.562.600 -88.37%
2002 1.060.655.610 8.87%
2003 2.634.591.540 59.74%
2004 681.616.320 -286.52%
2005 1.594.057.280 57.24%
2006 1.694.952.530 5.95%
2007 2.306.000.000 26.5%
2008 1.719.000.000 -34.15%
2009 1.359.000.000 -26.49%
2010 1.301.000.000 -4.46%
2011 2.470.000.000 47.33%
2012 2.403.000.000 -2.79%
2013 3.189.000.000 24.65%
2014 3.426.000.000 6.92%
2015 4.110.000.000 16.64%
2016 4.531.000.000 9.29%
2017 3.248.000.000 -39.5%
2018 1.695.000.000 -91.62%
2019 2.430.000.000 30.25%
2020 -15.561.000.000 115.62%
2021 1.000.000.000 1656.1%
2022 4.150.000.000 75.9%
2023 -18.276.000.000 122.71%
2023 -2.941.000.000 -521.42%
2024 -136.000.000 -2062.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bayer Aktiengesellschaft Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 1
1999 1 0%
2000 1 0%
2001 0 0%
2002 0 0%
2003 1 0%
2004 0 0%
2005 0 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 0 0%
2010 0 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 100%
2015 1 0%
2016 1 0%
2017 1 0%
2018 0 0%
2019 2 100%
2020 -16 113.33%
2021 1 1600%
2022 4 75%
2023 -5 200%
2023 -3 -100%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bayer Aktiengesellschaft Free Cashflow
Year Free Cashflow Growth
1998 145.000.000
1999 621.000.000 76.65%
2000 445.061.320 -39.53%
2001 1.244.168.370 64.23%
2002 2.182.301.300 42.99%
2003 1.637.289.860 -33.29%
2004 1.197.992.320 -36.67%
2005 2.111.619.310 43.27%
2006 2.326.865.990 9.25%
2007 2.423.000.000 3.97%
2008 1.849.000.000 -31.04%
2009 3.800.000.000 51.34%
2010 4.259.000.000 10.78%
2011 3.445.000.000 -23.63%
2012 2.603.000.000 -32.35%
2013 3.014.000.000 13.64%
2014 3.439.000.000 12.36%
2015 4.373.000.000 21.36%
2016 6.511.000.000 32.84%
2017 5.768.000.000 -12.88%
2018 5.324.000.000 -8.34%
2019 5.557.000.000 4.19%
2020 2.485.000.000 -123.62%
2021 2.478.000.000 -0.28%
2022 4.144.000.000 40.2%
2023 1.311.000.000 -216.09%
2023 1.893.000.000 30.74%
2024 1.273.000.000 -48.7%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bayer Aktiengesellschaft Operating Cashflow
Year Operating Cashflow Growth
1998 2.848.000.000
1999 3.253.000.000 12.45%
2000 3.099.458.140 -4.95%
2001 3.866.250.400 19.83%
2002 4.423.686.740 12.6%
2003 3.287.284.200 -34.57%
2004 2.448.359.920 -34.26%
2005 3.499.664.950 30.04%
2006 4.202.906.430 16.73%
2007 4.283.000.000 1.87%
2008 3.608.000.000 -18.71%
2009 5.375.000.000 32.87%
2010 5.773.000.000 6.89%
2011 5.060.000.000 -14.09%
2012 4.532.000.000 -11.65%
2013 5.171.000.000 12.36%
2014 5.810.000.000 11%
2015 6.890.000.000 15.67%
2016 9.089.000.000 24.19%
2017 8.134.000.000 -11.74%
2018 7.917.000.000 -2.74%
2019 8.207.000.000 3.53%
2020 4.903.000.000 -67.39%
2021 5.089.000.000 3.65%
2022 7.093.000.000 28.25%
2023 4.062.000.000 -74.62%
2023 2.576.000.000 -57.69%
2024 1.901.000.000 -35.51%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bayer Aktiengesellschaft Capital Expenditure
Year Capital Expenditure Growth
1998 2.703.000.000
1999 2.632.000.000 -2.7%
2000 2.654.396.820 0.84%
2001 2.622.082.030 -1.23%
2002 2.241.385.440 -16.98%
2003 1.649.994.340 -35.84%
2004 1.250.367.600 -31.96%
2005 1.388.045.640 9.92%
2006 1.876.040.440 26.01%
2007 1.860.000.000 -0.86%
2008 1.759.000.000 -5.74%
2009 1.575.000.000 -11.68%
2010 1.514.000.000 -4.03%
2011 1.615.000.000 6.25%
2012 1.929.000.000 16.28%
2013 2.157.000.000 10.57%
2014 2.371.000.000 9.03%
2015 2.517.000.000 5.8%
2016 2.578.000.000 2.37%
2017 2.366.000.000 -8.96%
2018 2.593.000.000 8.75%
2019 2.650.000.000 2.15%
2020 2.418.000.000 -9.59%
2021 2.611.000.000 7.39%
2022 2.949.000.000 11.46%
2023 2.751.000.000 -7.2%
2023 683.000.000 -302.78%
2024 628.000.000 -8.76%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bayer Aktiengesellschaft Equity
Year Equity Growth
1998 12.779.000.000
1999 15.182.000.000 15.83%
2000 16.422.549.760 7.55%
2001 17.049.714.700 3.68%
2002 15.468.609.040 -10.22%
2003 12.314.611.270 -25.61%
2004 12.369.418.240 0.44%
2005 10.904.263.650 -13.44%
2006 12.851.180.090 15.15%
2007 16.821.000.000 23.6%
2008 16.340.000.000 -2.94%
2009 18.951.000.000 13.78%
2010 18.896.000.000 -0.29%
2011 19.271.000.000 1.95%
2012 18.569.000.000 -3.78%
2013 20.804.000.000 10.74%
2014 20.218.000.000 -2.9%
2015 25.445.000.000 20.54%
2016 31.897.000.000 20.23%
2017 36.861.000.000 13.47%
2018 46.148.000.000 20.12%
2019 47.517.000.000 2.88%
2020 30.699.000.000 -54.78%
2021 33.168.000.000 7.44%
2022 38.926.000.000 14.79%
2023 33.547.000.000 -16.03%
2023 33.078.000.000 -1.42%
2024 35.847.000.000 7.72%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bayer Aktiengesellschaft Assets
Year Assets Growth
1998 29.377.000.000
1999 31.279.000.000 6.08%
2000 36.552.524.200 14.43%
2001 37.103.640.830 1.49%
2002 41.729.603.330 11.09%
2003 37.379.756.280 -11.64%
2004 37.775.855.120 1.05%
2005 36.694.556.910 -2.95%
2006 55.891.002.850 34.35%
2007 51.378.000.000 -8.78%
2008 52.511.000.000 2.16%
2009 51.042.000.000 -2.88%
2010 51.506.000.000 0.9%
2011 52.765.000.000 2.39%
2012 51.336.000.000 -2.78%
2013 51.317.000.000 -0.04%
2014 70.234.000.000 26.93%
2015 73.917.000.000 4.98%
2016 82.238.000.000 10.12%
2017 75.087.000.000 -9.52%
2018 126.285.000.000 40.54%
2019 126.258.000.000 -0.02%
2020 117.046.000.000 -7.87%
2021 120.241.000.000 2.66%
2022 124.877.000.000 3.71%
2023 117.242.000.000 -6.51%
2023 123.344.000.000 4.95%
2024 119.859.000.000 -2.91%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bayer Aktiengesellschaft Liabilities
Year Liabilities Growth
1998 16.598.000.000
1999 16.097.000.000 -3.11%
2000 20.129.974.440 20.03%
2001 20.053.926.130 -0.38%
2002 26.260.994.290 23.64%
2003 25.065.145.010 -4.77%
2004 25.406.436.880 1.34%
2005 25.790.293.260 1.49%
2006 43.039.822.760 40.08%
2007 34.557.000.000 -24.55%
2008 36.171.000.000 4.46%
2009 32.091.000.000 -12.71%
2010 32.610.000.000 1.59%
2011 33.494.000.000 2.64%
2012 32.767.000.000 -2.22%
2013 30.513.000.000 -7.39%
2014 50.016.000.000 38.99%
2015 48.472.000.000 -3.19%
2016 50.341.000.000 3.71%
2017 38.226.000.000 -31.69%
2018 80.137.000.000 52.3%
2019 78.741.000.000 -1.77%
2020 86.347.000.000 8.81%
2021 87.073.000.000 0.83%
2022 85.951.000.000 -1.31%
2023 83.695.000.000 -2.7%
2023 90.266.000.000 7.28%
2024 84.012.000.000 -7.44%

Bayer Aktiengesellschaft Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
47.96
Net Income per Share
-1.29
Price to Earning Ratio
-5.7x
Price To Sales Ratio
0.61x
POCF Ratio
0.95
PFCF Ratio
6.01
Price to Book Ratio
0.2
EV to Sales
1.52
EV Over EBITDA
6.11
EV to Operating CashFlow
9.47
EV to FreeCashFlow
14.9
Earnings Yield
-0.18
FreeCashFlow Yield
0.17
Market Cap
28,86 Bil.
Enterprise Value
71,55 Bil.
Graham Number
32.45
Graham NetNet
-55.65

Income Statement Metrics

Net Income per Share
-1.29
Income Quality
-5.93
ROE
-0.04
Return On Assets
-0.01
Return On Capital Employed
0.04
Net Income per EBT
5.75
EBT Per Ebit
-0.05
Ebit per Revenue
0.07
Effective Tax Rate
-4.36

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.12
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.57
Operating Profit Margin
0.07
Pretax Profit Margin
-0
Net Profit Margin
-0.02

Dividends

Dividend Yield
0
Dividend Yield %
0.29
Payout Ratio
-0.09
Dividend Per Share
0.02

Operating Metrics

Operating Cashflow per Share
7.69
Free CashFlow per Share
4.89
Capex to Operating CashFlow
0.36
Capex to Revenue
0.06
Capex to Depreciation
0.34
Return on Invested Capital
0.76
Return on Tangible Assets
-0.02
Days Sales Outstanding
131.94
Days Payables Outstanding
113.2
Days of Inventory on Hand
241.82
Receivables Turnover
2.77
Payables Turnover
3.22
Inventory Turnover
1.51
Capex per Share
2.8

Balance Sheet

Cash per Share
10,20
Book Value per Share
36,49
Tangible Book Value per Share
-20.39
Shareholders Equity per Share
36.33
Interest Debt per Share
50.35
Debt to Equity
1.31
Debt to Assets
0.39
Net Debt to EBITDA
3.65
Current Ratio
1.27
Tangible Asset Value
-20,03 Bil.
Net Current Asset Value
-43,87 Bil.
Invested Capital
77951000000
Working Capital
8,58 Bil.
Intangibles to Total Assets
0.47
Average Receivables
17,41 Bil.
Average Payables
6,26 Bil.
Average Inventory
13262500000
Debt to Market Cap
1.61

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bayer Aktiengesellschaft Dividends
Year Dividends Growth
2001 1
2002 1 0%
2003 1 100%
2004 1 0%
2005 1 0%
2006 1 100%
2007 2 0%
2008 3 66.67%
2009 2 -50%
2010 2 0%
2011 3 33.33%
2012 3 -50%
2013 3 33.33%
2014 4 0%
2015 3 -50%
2016 3 33.33%
2017 3 0%
2018 1 -200%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%
2024 0 0%

Bayer Aktiengesellschaft Profile

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

CEO
Mr. William N. Anderson
Employee
96.931
Address
Kaiser-Wilhelm-Allee 1
Leverkusen, 51368

Bayer Aktiengesellschaft Executives & BODs

Bayer Aktiengesellschaft Executives & BODs
# Name Age
1 Dr. Jost Reinhard
Head of Investor Relations
70
2 Mr. Rodrigo Santos
Member of Management Board & President of the Crop Science Division
70
3 Dr. Sebastian Guth Ph.D.
Chief Operating Officer
70
4 Mr. Wolfgang U. Nickl
Chief Financial Officer & Member of Management Board
70
5 Ms. Heike Prinz
Chief Talent Officer, Labor Director & Member of Management Board
70
6 Mr. Julio Triana
Member of Management Board & President of Consumer Health Division
70
7 Amanda McClerren
Chief Information Officer, Head-Digital Transformation & IT-Crop Science Division
70
8 Mr. William N. Anderson
Chairman of the Management Board & Chief Executive Officer
70
9 Mr. Stefan Oelrich
Head of the Pharmaceuticals Division & Member of the Board of Management
70
10 Dr. Thomas Laubert
Head of Law, Patents & Compliance
70

Bayer Aktiengesellschaft Competitors

Novartis AG Logo
Novartis AG

NVS

(2.0)
Sanofi Logo
Sanofi

SNY

(3.0)
AstraZeneca PLC Logo
AstraZeneca PLC

AZN

(3.0)
GSK plc Logo
GSK plc

GSK

(2.2)
Roche Holding AG Logo
Roche Holding AG

RHHBY

(2.5)
Merck & Co., Inc. Logo
Merck & Co., Inc.

MRK

(2.2)